You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Chronic Kidney Disease in Type 2 Diabetes: Patient Selection and Education for Improved Outcomes

  • Authors: George Bakris, MD
  • CME / CE Released: 9/22/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/22/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for diabetologists, endocrinologists, nephrologists, and primary care physicians.

The goal of this activity is for learners to be better able to screen and diagnose patients who have type 2 diabetes (T2D) for kidney disease and initiate appropriate treatment.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Management of CKD in patients with T2D
    • Patient education related to the management of CKD in T2D


Disclosures

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • George Bakris, MD

    Professor of Medicine
    Director, ASH Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, Illinois

    Disclosures

    George Bakris, MD, has the following relevant financial relationships:
    Consultant or advisor for: Alnylam; AstraZeneca; Bayer; DiaMedica Therapeutics; Horizon Pharma; Ionis Pharmaceuticals; KBP BioSciences; Merck; Novo Nordisk; Quantum Genomics
    Research funding from: Bayer

Editors

  • Anne G. Le, PharmD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Anne G. Le, PharmD, has no relevant financial relationships.

  • Gina Montanero, PharmD, RPh

    Associate Medical Writer, Medscape, LLC

    Disclosures

    Gina Montanero, PharmD, RPh, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a collaboration between Medscape and University of Chicago.

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • The University Of Chicago Pritzker School Of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Other Healthcare Professions Credit

    Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

    Contact this Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-22-351-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Chronic Kidney Disease in Type 2 Diabetes: Patient Selection and Education for Improved Outcomes

Authors: George Bakris, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 9/22/2022

Valid for credit through: 9/22/2023, 11:59 PM EST

processing....

Josephine, a 56-year-old woman has been referred to a new primary care clinician by her friend. Josephine has a 10-year history of type 2 diabetes, 20-year history of hypertension, class 1 obesity (body mass index [BMI] = 32 kg/m2), dyslipidemia. She has no history of cardiac disease and has a family history of type 2 diabetes, hypertension, and cancer (breast).

Prior medical record: glycated hemoglobin (HbA1c) 7.9%, estimated glomerular filtration rate (eGFR) 50mL/min/1.73m2, serum creatinine 1.5 mg/dL, blood pressure 146/86 mmHg, potassium 4.3 mEq/L, total cholesterol 265 mg/dL.

Current Medications: glyburide 5 mg daily, metformin 1000 mg twice daily, amlodipine 5 mg daily, lisinopril 10 mg daily, hydrochlorothiazide 12.5 mg daily, and atorvastatin 10 mg daily.

 
  • Print